NLRP3:对于炎症性肠病来说是一个有前途的治疗标
Jiayu Zhang1,2, Shuyan Zeng1,2, Peng Wang1
1Department of Gastroenterology, Digestive Disease Hospital, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Current drug targets
|November 10, 2023
概括
在炎症性肠病 (IBD) 中,NLRP3炎症体具有双重作用,可能通过异常激活驱动疾病的进展,或通过维持免疫平衡来提供保护. 准NLRP3为IBD治疗提供了新的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
背景情况:
- 炎症性肠病 (IBD),包括克罗恩病和性结肠炎,呈现出复杂的病理,发病率越来越高.
- NLRP3炎症酶与肠道免疫反应和平衡有关,因此它是IBD病变发生的关键因素.
研究的目的:
- 审查NLRP3炎症酶的激活机制.
- 分析NLRP3炎症酶激活在IBD中的双重作用,考虑病理和保护性方面.
- 探索NLRP3炎症酶抑制剂作为IBD的潜在治疗点.
主要方法:
- 关于NLRP3炎症酶激活途径的文献综述.
- 对研究NLRP3在IBD病理和保护中的作用的研究分析.
- 收集有关各种NLRP3抑制剂 (直接,间接,自然) 和它们对IBD的影响的数据.
主要成果:
- 异常的NLRP3激活通过释放促炎细胞因子促进IBD.
- 此外,NLRP3还可以通过维持免疫系统平衡来对肠道产生保护作用.
- 针对NLRP3的各种抑制剂在临床前和临床环境中对IBD管理有希望.
结论:
- NLRP3炎症酶是IBD的关键参与者,在疾病的发展和解决中起着复杂的作用.
- 针对NLRP3激活是一个有前途的IBD治疗途径.
- 对NLRP3抑制剂的进一步研究可能会导致IBD患者的创新治疗方法.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
147
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
147
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
338
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
338
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
Drugs for Treatment of Ulcerative Colitis in IBD
146
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
146
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
122
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
122


